Abstract Number: VPB0004
Meeting: ISTH 2022 Congress
Theme: Acquired Bleeding Disorders » Management/Treatments of Acquired Bleeding
Background: Acquired von Willebrand syndrome (AVWS) is a probably under-diagnosed hemorrhagic condition, clinically similar to congenital von Willebrand disease (VWD), normally associated with other underlying conditions. Diagnostic of AVWS includes clinical symptomatology and a complex battery of laboratory tests. The utility of BAT (ISTH-SCC bleeding assessment tool) questionnaire in the diagnostic of AVWS was not evaluated. In VWD BAT ≥ 3 is considered abnormal.
Aims: Describe path to diagnosis of AVWS and evaluate the utility of BAT questionnaire in AVWS.
Methods: We evaluated BAT questionnaire, and VWF laboratory test in patients with suspicion of AVWS (presence of underlying disease related with AVWS and recent hemorrhagic diathesis or high risk of hemorrhage). Laboratory study included: platelet function assay (PFA), ristocetin induced platelet agglutination (RIPA), VWF antigen (VWF:Ag), VWF ristocetin cofactor (VWF:RCo), VWF collagen binding (VWF:CB) and ratios, and VWF multimeric distribution (SDS-agarose gel). Patients with 2-3 laboratory criteria were included in AVWS group, and with 1-0 criteria, in Control group (Table 1).
Results: A total of 82 patients were enrolled: 68 with CVD (cardiovascular disease), 6 with MG (monoclonal gammopathy), 5 with ET (essential thrombocytemia), 2 with cancer, and 1 with lupus. AVWS was confirmed in 50 (60.9%) patients and Control group 32 (39%). Probability of BAT ≥ 3 being related with AVWS diagnostic was 92% (OR=12.7, CI 95% 3,9 – 40.9). There was significant difference in BAT values comparing AVWS group with Control group (Table 2). AVWS patients that were bleeders in moment of diagnosis had BAT > 3 (mean) in all underlying diseases except for ET. In Control group BAT was ≤ 3 despite presence of bleed.
Conclusion(s): Results suggest that BAT questionnaire is useful for the diagnostic of AVWS. Larger studies are necessary to compare BAT results in different underlying diseases and evaluate utility in hemorrhagic risk evaluation.
Table 1. Laboratory criteria for the diagnostic of AVWS
Patients with 3 or 2 laboratory criteria were included in AVWS group; Patients with 1 or 0 criteria were included in Control group.
LLN: lower limit of normality; PFA-100 -platelet function assay-; RIPA -ristocetin induced platelet agglutination-; ULN: upper limit of normality; VWF: von Willebrand factor; VWF:Ag: VWF antigen; VWF:CB: VWF collagen binding assay; VWF:RCo: VWF ristocetin cofactor activity.
Results of BAT questionnaire in all patients enrolled and according to underlying disease
BAT normal value < 3.
AVWS: acquired von Willebrand syndrome; BAT: ISTH-SSC bleeding assessment tool; CVD: cardiovascular disease; ET: essential thrombocytemia; MG: monoclonal gammopathy; SD: standard deviation.
To cite this abstract in AMA style:
Costa-Pinto M, Fernández M, Rodríguez N, Pérez-Rodríguez A, Gómez-del-Castillo M, Lado T, Lopez-Fernandez M. Evaluation of the utility of BAT (ISTH-SSC bleeding assessment tool) questionnaire in the diagnostic of acquired von Willebrand syndrome [abstract]. https://abstracts.isth.org/abstract/evaluation-of-the-utility-of-bat-isth-ssc-bleeding-assessment-tool-questionnaire-in-the-diagnostic-of-acquired-von-willebrand-syndrome/. Accessed October 1, 2023.« Back to ISTH 2022 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/evaluation-of-the-utility-of-bat-isth-ssc-bleeding-assessment-tool-questionnaire-in-the-diagnostic-of-acquired-von-willebrand-syndrome/